Adaptive Biotechnologies Corp
ADPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.24B
Close$
$-24.72
196.6% downside
Current Fair Value
196.6% downsideOvervalued by 196.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.24 Billion |
|---|---|
| Enterprise Value | $4.53 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 2.1 |
| Outstanding Shares | 157,700,126 |
Return
| Return on Equity | -44.68% |
|---|---|
| Return on Assets | -9.97% |
| Return on Invested Capital | -6.60% |
Valuation & Multiples
| P/E Ratio | -65.02 |
|---|---|
| PEG | -117.5 |
| Price to Sales | 25.58 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14.72 |
| Enterprise Value to EBIT | -124.31 |
| Enterprise Value to Net Income | -71 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 3.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$65.44 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$71.57 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 0.46% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 398.20% |
|---|---|
| Total Invested | $1.29M▼ 99.96% |
| Investors Holding | 8▼ 301.00% |
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...